The rationality guidance index: a framework for reducing redundancy in nanomedicine innovation.

Nanocarriers have transformed drug delivery by improving bioavailability, enabling targeted action, and reducing systemic toxicity. Despite these advances, the field has become saturated with structurally and functionally similar platforms, leading to redundancy and limited translational progress. This work critically analyzes the scientific and systemic drivers of redundancy, including design convergence, patent-driven modifications, novelty-focused academic incentives, and insufficient comparative standards. To address these challenges, a rational innovation framework is proposed, grounded in needs-based design, comparative benchmarking, predictive modeling, and resource-conscious decision-making. Within this framework, the Rationality Guidance Index (RGI) is introduced as a semi-quantitative pre-initiation triage tool that balances clinical need, innovation value, and translational feasibility. Designed for academic and innovator contexts, the RGI complements existing frameworks such as DELIVER and the 6Rs roadmap by identifying projects at high risk of redundancy before resource-intensive development. The adoption of rational innovation strategies, supported by structured decision-making tools, is essential to enhance clinical success rates and ensure that advances in nanomedicine translate into meaningful patient outcomes.